Skip to NavigationSkip to content

News

0
Pharmafile's top 10 news roundup
The last week has seen its fair share of COVID-19 vaccine developments; Bharat Biotech’s candidate was found to be 81% effective, while a UK study...
0
Roche building
Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated...
0
Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9...
0
CureVac and Novartis have signed an initial agreement for the manufacturing of CureVac’s COVID-19 vaccine candidate, CVnCoV.

Features

Early and managed access programmes provide opportunities for patients to get the treatments they need faster - but the COVID-19 pandemic has...